Orikine Bio closes €5.5m series seed financing with Sabadell Asabys and AdBio - #BHHMembersInitiatives
Home News Orikine Bio closes €5.5m series seed financing with Sabadell Asabys and AdBio - #BHHMembersInitiatives

Orikine Bio closes €5.5m series seed financing with Sabadell Asabys and AdBio - #BHHMembersInitiatives

JULY 18, 2023 BHH News
Orikine Bio, a biotech company developing a novel proprietary platform for cytokine-based therapies for autoimmune and inflammatory diseases, announces the successful closing of a €5.5m seed financing that will support the company to advance candidates through pre-clinical development. BHH member Asabys Partners, Barcelona-based VC firm focused on healthcare innovation investing from its fund Sabadell Asabys II, joins AdBio Partners, French life sciences venture capital firm and initial investor. Orikine Bio is a spin-off from the Centre for Genomic Regulation (CRG) in Barcelona and was co-founded by Dr. Luis Serrano, Dr. Ariadna Montero, Dr. Javier Delgado, Dr. Alejo Chorny and AdBio Partners in 2022. The company’s unique synthetic biology platform delivers optimized and novel engineered cytokines called Foldikines©. Cytokines are proteins that are produced by the immune system and act as soluble messengers that control the entire range of immune responses, including their initiation, type, potency, and duration. Thus, dysregulated cytokine signaling triggers a wide variety of inflammatory and autoimmune diseases, allergies, fibrosis, and cancer. Orikine Bio's Foldikines© have unique biological activities that are not available for natural cytokines, making them highly attractive as new drugs for therapeutic interventions. Currently, the company is validating the first Foldikine© candidates, which will advance to the pre-clinical stage with this new funding. The initial focus of the company is to advance these improved cytokines into clinical development for new therapies targeting autoimmune and inflammatory diseases. However, the versatility of the platform developed by Dr. Luis Serrano and his team will allow the development of new drugs for a wide range of immune-based diseases. Luis Serrano, co-founder of Orikine Bio and Director of the CRG, mentions: “Orikine Bio is the fifth spin-off launched by the Centre for Genomic Regulation in a short period of time, demonstrating that curiosity-driven research is a critical source for new idea generation and solutions for patients. The creation of this company has been possible thanks to the development of cutting-edge computational and experimental tools combined with decades of expertise in biochemistry”. Dr. Ariadna Montero, co-founder and Head of Biology at Orikine Bio, adds: “Protein design is a highly-precise task requiring accurate algorithms to generate reliable results. Our unique computational approach makes the process of protein design highly flexible and adaptable to almost any target, speeding up the development process for new drugs.” Sylvain Sachot, Partner at Asabys Partners, states “Orikine Bio’s uniqueness resides in the company’s profound understanding of the immunological processes underlying autoimmune and inflammatory diseases and its ability to modulate these anomalies. The company is targeting a large medical need, and we look forward to working with the management in developing and bringing new immune modulators to the market". “Orikine Bio's Foldikines© could become blockbusters drugs in immunology and this immediately convinced us of the potential of the project. We were highly motivated to cofound the company and shape the initial business plan. We are delighted to welcome Asabys Partners in the Seed Financing, all ingredients are in place for Orikine Bio to become a leader in its space” explains Clement Bertholet, MsC, Partner at AdBio. Alejo Chorny, Co-founder and CEO of Orikine Bio, adds “We are delighted to announce the successful completion of our seed financing round, a significant milestone for our biotech company focused on engineered cytokines for immune-mediated diseases. This funding injection not only validates the tremendous potential of our approach but also provides us with the resources to advance our groundbreaking work. We are grateful for the support and confidence shown by our investors and remain committed to delivering transformative therapies that have the power to reshape the lives of patients battling immune-mediated diseases worldwide”.
February 16, 2024 4YFN BHH News
BHH ON AIR with 4YFN at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
February 01, 2024 BHH News
BHH ON AIR with Astrazeneca at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
January 24, 2024 BHH News
Sanofi reinforces its commitment to digital innovation by joining Barcelona Health Hub
The company consolidates its position in the city's digital health ecosystem, where its Global Innovation Center is located.
Read more
January 18, 2024 BHH News
Novo Nordisk joins Barcelona Health Hub to drive digital solutions applied to healthcare
Novo Nordisk takes another step forward in its efforts to improve the quality of life of patients as part of its commitment to innovation.
Read more
January 11, 2024 BHH News
BHH ON AIR with Qualifyze at Revolució 4.0 at Catalunya Ràdio
If you’re looking for a quick catch-up about all things related to digital health, don’t miss BHH this weekend at Catalunya Ràdio!
Read more
January 11, 2024 BHH News
Let’s welcome the new BHH Ambassadors
Barcelona Health Hub is proud to start the new year with brand new BHH Ambassadors!
Read more
January 02, 2024 BHH News
Special discounts for BHH Residents
Check out these special discounts available for BHH Residents. 
Read more
December 28, 2023 BHH News
#BHHInterview with COCO
Barcelona Health Hub had the pleasure to meet up with Robert Parada, CEO of BHH member COCO Tecnologías a few weeks ago.
Read more
December 28, 2023 BHH News
Sign up for InnoBuyer's Open Call for Solvers
The InnoBuyer Call for Solvers aims to select 15 innovative SMEs (Solvers), to co-develop pilots with public organisations (Challengers).
Read more
December 20, 2023 BHH News
BHH opened its 4th pavilion!
The digital health ecosystem of Barcelona Health Hub is growing every day. More than 500 healthcare companies and organizations form part of the community and this number is increasing on a daily basis.
Read more